This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Psychiatric Research Issues Raised by Protease Inhibitor Treatments for People With the Human Immunodeficiency Virus or the Acquired Immunodeficiency Syndrome

Judith G. Rabkin, PhD, MPH; Stephen Ferrando, MD

Arch Gen Psychiatry. 1997;54(11):1049-1053.

Abstract
Seldom in the history of medicine has an entire generation of patients with an incurable, progressive, and ultimately fatal disease suddenly been offered the prospect of extended survival and even, perhaps, a "second life." The relatively simultaneous appearance of 2 major treatment developments has created profound changes in therapeutic options and outlook. The first development is an assay of serum levels of human immunodeficiency virus viral copies, providing a critical tool for clinical decision making. The second is the marketing between December 1995 and April 1997 of 4 human immunodeficiency virus protease inhibitors that, combined with previously available antiviral medications, achieve a new level of efficacy. With the advent of these changes come multiple psychiatric research and policy issues. These include the development of strategies to establish and maintain medication adherence. This is a critical task, given the complexity of combination therapy regimens and the rapid onset of viral resistance to protease inhibitors within days to weeks of missed or suboptimal dosing. The psychological issues to be studied include the process of restructuring lives and expectations in the event of clinical benefit or managing the distress associated with clinical failure. Other research questions include the effects of restored health on the appraisal of human immunodeficiency virus risk behaviors, assessment of effect of neurocognitive functioning, and unanswered questions about psychotropic or protease inhibitor drug interactions due to their shared metabolic pathways. Behavioral scientists can inform provision of care to patients who may be considered difficult to treat, such as those with severe and persistent mental illness or active substance abuse or the homeless. This includes the provision of empirical data regarding individual and situational characteristics that are likely to promote or impede adherence, as well as innovative provision systems. Psychiatry can make notable contributions during this turning point in human immunodeficiency virus therapeutics and research.

Author Affiliations
From the Department of Psychiatry, Cornell University Medical College, New York, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How Do Subjectively-Constructed Meanings Ascribed to Anti-HIV Treatments Affect Treatment-Adherent Practice?
Wong and Ussher
Qual Health Res 2008;18:458-468.
ABSTRACT  

The Physical, Emotional and Interpersonal Impact of HAART: Exploring the Realities of HIV Seropositive Individuals on Combination Therapy
Halkitis et al.
J Health Psychol 2005;10:345-358.
ABSTRACT  

Psychosocial Characteristics of New York City HIV-Infected Women Before and After the Advent of HAART
Siegel et al.
AJPH 2004;94:1127-1132.
ABSTRACT | FULL TEXT  

Overcoming the False Dichotomy of Curative vs Palliative Care for Late-Stage HIV/AIDS: "Let Me Live the Way I Want to Live, Until I Can't"
Selwyn and Forstein
JAMA 2003;290:806-814.
ABSTRACT | FULL TEXT  

Lazarus and Group Psychotherapy: AIDS in the Era of Protease Inhibitors
Gushue and Brazaitis
The Counseling Psychologist 2003;31:314-342.
ABSTRACT  

Psychiatric Aspects of HIV Care
AIDS Clin Care 2001;2001:6-6.
FULL TEXT  

Challenges Associated With Increased Survival Among Parents Living With HIV
Lee and Rotheram-Borus
AJPH 2001;91:1303-1309.
ABSTRACT | FULL TEXT  

Dealing with AIDS-related loss and grief in a time of treatment advances
Demmer
AM J HOSP PALLIAT CARE 2001;18:35-41.
ABSTRACT  

Psychosocial Issues in the Era of New AIDS Treatments from the Perspective of Persons Living with HIV
Bogart et al.
J Health Psychol 2000;5:500-516.
ABSTRACT  

Psychological Effects of HAART: A 2-Year Study
Rabkin et al.
Psychosom. Med. 2000;62:413-422.
ABSTRACT | FULL TEXT  

Fluoxetine Treatment for Depression in Patients With HIV and AIDS: A Randomized, Placebo-Controlled Trial
Rabkin et al.
Am. J. Psychiatry 1999;156:101-107.
ABSTRACT | FULL TEXT  

Suicidal Ideation, Suicide Attempts, and HIV Infection
Kelly et al.
Psychosomatics 1998;39:405-415.
ABSTRACT | FULL TEXT